Thus, our results not only demonstrate the clinical relevance of our experimental findings in mice, but also support the potential efficacy of soluble recombinant human P-selectin for treating human cancers via the neutralization of platelet deposition and inhibition of tumor growth. This evidence concerns the gene SELP and cancer.